DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Excision margins, sentinel-node and follow-up concepts

Essential points for quick revision.

Synopsis

Explain the sequence from diagnostic melanoma excision to stage-based wide local excision, select sentinel-node discussion using current NICE criteria, and design follow-up around recurrence risk, skin surveillance and patient support.

  • Diagnostic excision removes the suspicious lesion completely with a narrow margin to establish melanoma diagnosis, Breslow depth, ulceration and pathological stage.
  • Wide local excision is a second procedure around the biopsy scar; its clinical margin is determined by stage and includes the initial primary-lesion margin.
  • NICE advises at least 0.5 cm for stage 0, 1 cm for stage I and 2 cm for stage II, using 1 cm if a 2 cm margin would cause unacceptable disfigurement or morbidity.

Key red flags

A new scar nodule, in-transit dermal lesion, firm regional node, persistent focal pain, neurological deficit, unexplained weight loss or respiratory symptoms after melanoma requires urgent specialist reassessment rather than waiting for routine follow-up.

In-transit recurrence

A new dermal or subcutaneous nodule between the primary scar and draining nodal basin can represent lymphatic melanoma spread.

Investigation priorities

01
Complete diagnostic histopathologyFirst step

Provide Breslow thickness, ulceration, margins and adverse features before definitive planning.

Management branches

After diagnostic excisionConvert histology into local control

A completely sampled primary lesion is confirmed as stage 0, I or II melanoma.

  1. Review Breslow depth, ulceration, biopsy margins and stage in the specialist skin-cancer multidisciplinary team.
  2. Plan wide local excision around the histological scar using at least 0.5 cm for stage 0, 1 cm for stage I and 2 cm for stage II unless morbidity dictates the NICE alternative.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom